Home › Therapeutic areas › Oncology › Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma (6 companies)
Companies with an active program in Cutaneous Squamous Cell Carcinoma.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| DRTS | Alpha Tau Medical | Oncology | 1 | Phase 2 | $1.27B | 6 |
| BCAX | Bicara Therapeutics | Oncology | 1 | Phase 2 | $572M | 4 |
| FBIO | Fortress Biotech | DermatologyHematology+3 Rare | 1 | Approved | $61.7M | 12 |
| PHIO | Phio Pharmaceuticals | Oncology | 1 | Phase 1 | $9.6M | 4 |
| REPL | Replimune Group | Oncology | 1 | Approved | $2.05B | 5 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 1 | Phase 3 | $2.09B | 12 |
No companies match.